Decreased synovial fluid ghrelin levels are linked with disease severity in primary knee osteoarthritis patients and are increased following laser therapy

What Was Tested

The paper reports a study of Ghrelin, published as a randomized controlled trial.

The current study was performed to explore the serum and synovial ghrelin levels as well as the relationship between ghrelin levels and disease severity in primary knee OA patients.

The Receiver Operating Characteristic (ROC) analysis curve was conducted to test the diagnostic value of ghrelin, IL-6 and TNF-α for radiographic progression.

Why It Was Studied

Ghrelin has been proved to inhibit inflammation and promote cartilage growth.

So far, its role in patients with primary knee osteoarthritis has not been investigated.

Who Took Part

The study group was 52 patients.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

52 primary knee OA patients were recruited in the study. 52 sex and age-matched patients visiting their hospital for regular body check were selected as controls.

The serum and synovial fluid ghrelin levels were examined by enzyme linked immunosorbent assay (ELISA) before treatment, one week and four weeks after laser therapy, respectively.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Ghrelin and who got the comparison, which limits bias.

The inflammation markers IL-6 and TNF-α were also investigated.

The radiographic progression was assessed by Kellgren-Lawrence (K-L) grade scale and the symptomatic severity was evaluated by visual analog scale (VAS), Lequesne index and Lysholm scores.

What Was Measured

So far, its role in patients with primary knee osteoarthritis has not been investigated.

PubMed files the paper under topics including Biomarkers, Ghrelin, Laser Therapy, Osteoarthritis, Knee, ROC Curve and Synovial Fluid.

Author keywords: Disease severity.

What This Means in Plain Language

The paper is a randomized study of Ghrelin in 52 patients.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Clinica chimica acta; international journal of clinical chemistry), a journal based in Netherlands.

More context: the Ghrelin compound page, all human trials.